Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
From J D Faccinetti – cofounder. In what is sure to be the first of many, Canada’s acromegaly community gathered in Vancouver for a two-day session filled with community, activity, and information. Patients, pituitary specialists,
Read this series of articles on subjects of interest to pituitary patients, their families and physicians including the patient’s perspective on diagnosis, rheumatic and bone disorders, undetected pituitary tumors, and mild traumatic brain injuries and pituitary
From Jorge D Faccinetti – cofounder Pituitary World News – In today’s podcasts we talk with Jill Sisco president of the Acromegaly Community, a leading acromegaly patient support group. Our candid discussion centers around patient support,
Today’s podcast is the first in an upcoming series of podcasts dedicated to pituitary lesions, with particular attention to pituitary adenomas. Dr. Blevins covers a variety of subjects including symptoms and signs, classification and groups,
From J D Faccinetti – cofounder – Recent news coverage from the Endocrine Society Annual Meeting features comments from Maria Fleseriu, MD, FACE, professor of medicine and neurological surgery at Oregon Health & Science University,
As some of you may know, my first cousin Carol Mackie Passera, who lives in the Patagonia region of Argentina and who developed acromegaly about the same time I did (read more here), runs a
From Jorge D. Faccinetti – co-founder – The Journal Pituitary published an article on the genetic background of acromegaly. The Authors, Mônica R. Gadelha, Leandro Kasuki and Márta Korbonits provide a great summary of current knowledge in the genetics of this disease. Read
From the desk of Lewis S Blevins Jr. MD – cofounder. I’m not sure this term really exists. It does, however, seem to be rather fitting at times. I encounter patients who look acromegalic but
From J D Faccinetti, cofounder: The endocrine team at Pfizer delivered some very smart changes to the Somavert injection delivery system, now with a diluent prefilled syringe. If you use Somavert let us know your
The European Society of Endocrinology recently published a pituitary update with several interesting presentations. Of particular note, for those of you interested in the genetics of acromegaly, is a presentation by Albert Beckers a Belgian
Listen to this engaging podcast where PWN cofounders Dr. Blevins and JD Faccinetti discuss the ins and outs of a Somavert (pegvisomant for injection) dose adjustment based on a recent case. . Don’t miss it!
In this podcast Dr Blevins discussed the drugs used to treat Acromegaly. Among other things, he discusses his perspectives for the proper selection of different drugs. Read more about Acromegaly and review the articles and